Results 191 to 200 of about 14,175 (245)

IL4I1⁺ Macrophages and TDO2⁺ Myofibroblasts Drive AhR‐Mediated Immunosuppression and Ferroptosis Resistance in Solid Predominant Lung Adenocarcinoma

open access: yesAdvanced Science, Volume 13, Issue 13, 3 March 2026.
Solid predominant lung adenocarcinoma exhibits an immune‐excluded, ferroptosis‐resistant niche enriched with IL4I1⁺ TAMs and TDO2⁺ myCAFs. Spatial and multi‐omics analyses reveal AhR‐driven crosstalk that promotes T cell exhaustion and therapy resistance. Blocking AhR with CH‐223191 restores ferroptosis sensitivity, and its combination with ferroptosis
Zhaoxuan Wang   +16 more
wiley   +1 more source

Attenuated Bacteria‐Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping Strategies

open access: yesAdvanced Science, Volume 13, Issue 16, 18 March 2026.
This review comprehensively overviews attenuated bacteria‐based tumor therapy, highlighting key methodologies and recent progress. It examines strategies for enhancing safety, stabilizing efficacy, optimizing manufacturing, and navigating regulatory pathways.
Yucheng Liu   +8 more
wiley   +1 more source

Combining anti-metabolic treatments with the repurposing of eribulin for glioblastoma: a clinical opportunity? [PDF]

open access: yesTransl Cancer Res
Audet-Walsh É   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy